The first inhibitors of oncogenic HH—GLI that were approved by the FDA for the treatment of advanced and metastatic basal cell carcinoma (BCC) were the small molecule SMO inhibitors (SMOi), vismodegib and sonidegib [18,19,20,21,22]. Here, SMO is linked to basal cell carcinoma.